TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30907298

Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study: 31449932

Group type: EXPERIMENTAL
Intervention: Standardized smoking cessation intervention (brief presentation by a vascular surgeon)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (2 weeks of free nicotine patches and referral to an outpatient smoking-cessation program)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 59
Study: 27477668

Group type: EXPERIMENTAL
Intervention: Targeted temperature management for 24 hours
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Targeted temperature management for 48 hours
Number of subjects: 161
Study: 25720675

Group type: EXPERIMENTAL
Intervention: Text messaging intervention for symptom awareness and diabetes knowledge
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no text messaging)
Number of subjects: 30
Study: 23177514

Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg once daily for the first 3 weeks of each 4 week cycle
Number of subjects: 760

Group type: COMPARATOR
Intervention: Placebo once daily for the first 3 weeks of each 4 week cycle
Number of subjects: 760

Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 760

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 760
Study: 22332549

Group type: EXPERIMENTAL
Intervention: Fentanyl (100 microg initial dose, adjusted by 5 microg intervals) with 0.0625% W/V bupivacaine
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Sufentanil (20 microg initial dose, adjusted by 1 microg intervals) with 0.0625% W/V bupivacaine
Number of subjects: 46

Group type: COMPARATOR
Intervention: Fentanyl and Sufentanil with 0.0625% W/V bupivacaine
Number of subjects: 46
Study: 19565824

Group type: EXPERIMENTAL
Intervention: Sodium levothyroxin and standard hypotensive therapy with ACE inhibitors
Number of subjects: 217

Group type: COMPARATOR
Intervention: Standard hypotensive therapy with ACE inhibitors
Number of subjects: 217
Study: 17014518

Group type: EXPERIMENTAL
Intervention: Daily dialysis (2 hr, 6 times weekly for 4 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Thrice‐weekly hemodialysis (4 hr for 4 weeks)
Number of subjects: 12
Study: 15486373

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) - triamcinolone acetonide (1200 microg daily)
Number of subjects: 1116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1116

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 1116
Study: 11190457

Group type: EXPERIMENTAL
Intervention: Hydrophilic guide wire
Number of subjects: 2

Group type: COMPARATOR
Intervention: Standard guide wire
Number of subjects: 2
Study: 9388109

Group type: EXPERIMENTAL
Intervention: Protamine administration and femoral sheath removal (group I, n = 117)
Number of subjects: 228

Group type: COMPARATOR
Intervention: No heparin neutralization and delayed sheath removal (group II, n = 111)
Number of subjects: 228
Study: 7956392

Group type: EXPERIMENTAL
Intervention: Enprofylline
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 348
Study: 3113599

Group type: EXPERIMENTAL
Intervention: Schwartz strain live measles vaccine
Number of subjects: 4500
Study: 30837416

Group type: EXPERIMENTAL
Intervention: 15.5% ferric sulfate (FS) with zinc oxide‐eugenol (ZOE)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 15.5% ferric sulfate (FS) with calcium hydroxide (CH)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 1.25% sodium hypochlorite (NaOCl) with zinc oxide‐eugenol (ZOE)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 1.25% sodium hypochlorite (NaOCl) with calcium hydroxide (CH)
Number of subjects: 29
Study: 28374931

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori infection
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Symptomatic HP
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Severity of HP symptoms
Number of subjects: 200
Study: 26597341

Group type: EXPERIMENTAL
Intervention: Geriatric Care Model (GCM)
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1147
Study: 25133856

Group type: EXPERIMENTAL
Intervention: Behavioral Training (BT)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Waitlist Control (WLC)
Number of subjects: 195
Study: 22251780

Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 79
Study: 19004600

Group type: EXPERIMENTAL
Intervention: Varenicline with phone counseling
Number of subjects: 1018

Group type: COMPARATOR
Intervention: Varenicline with Web support only
Number of subjects: 1018

Group type: EXPERIMENTAL
Intervention: Varenicline users
Number of subjects: 1018
Study: 17460178

Group type: EXPERIMENTAL
Intervention: Haplotype 4 (containing the ‐592A variant allele)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ‐2849AA carriers
Number of subjects: 0
Study: 15541060

Group type: EXPERIMENTAL
Intervention: Clinical nurse specialist care managers' activities in the Bipolar Disorders Program (BDP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total clinic time
Number of subjects: 0
Study: 10893282

Group type: EXPERIMENTAL
Intervention: SD/01 (30, 100, or 300 microg/kg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Daily filgrastim (5 microg/kg/d)
Number of subjects: 13
Study: 9372293

Group type: EXPERIMENTAL
Intervention: Active pursuit of moving target
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fixation on stationary target during moving display
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longer duration of target exposure (480 ms) with prior fixations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predictive response after target disappearance
Number of subjects: 0
Study: 1388334

Group type: EXPERIMENTAL
Intervention: Active medication in patients with DSM‐III melancholia (76 patients)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo in patients with DSM‐III melancholia (44 patients)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Active medication in patients without melancholia (76 patients)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo in patients without melancholia (35 patients)
Number of subjects: 231
Study: 3903068

Group type: EXPERIMENTAL
Intervention: Aspirin/dipyridamole combination
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 3550026

Group type: EXPERIMENTAL
Intervention: Conditioning therapy (n = 66)
Number of subjects: 121

Group type: COMPARATOR
Intervention: 3‐month waiting period (n = 55)
Number of subjects: 121
Study: 30898169

Group type: EXPERIMENTAL
Intervention: Training package (including videos, simulation, and Q&A sessions)
Number of subjects: 125
Study: 27761730

Group type: EXPERIMENTAL
Intervention: Tight glycemic control (4.4‐6.1 mM)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Loose glycemic control (6.7‐8.3 mM)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Tight glycemic control
Number of subjects: 15
Study: 26333022

Group type: EXPERIMENTAL
Intervention: Cognitive training program with 49 exercises targeting various cognitive capacities, completed for 15 minutes at least 5 days per week for 10 weeks.
Number of subjects: 4715

Group type: EXPERIMENTAL
Intervention: Cognitive training program
Number of subjects: 4715

Group type: COMPARATOR
Intervention: Active control condition (crossword puzzles)
Number of subjects: 4715
Study: 23886632

Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg loading dose followed by 75 mg/day)
Number of subjects: 177
Study: 21382044

Group type: EXPERIMENTAL
Intervention: Applied Muscle Tension (AMT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Distraction Control (repeated gentle foot flexions)
Number of subjects: 72
Study: 18498993

Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC) 0.02% (0.2 mg/mL)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Untreated (no eye treated with MMC)
Number of subjects: 81
Study: 16256250

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (400,000 IU)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (300 mg)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Vitamin A + Zinc supplementation
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 12655320

Group type: EXPERIMENTAL
Intervention: Ethanol 1.4 g/kg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 10706042

Group type: EXPERIMENTAL
Intervention: Oral acyclovir 800 mg four times daily for 120 days (ACV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir 5 mg/kg every 12 h for 14 days followed by ACV for 106 days (GCV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CMV disease
Number of subjects: 0

Group type: COMPARATOR
Intervention: Asymptomatic CMV infection
Number of subjects: 0

Group type: COMPARATOR
Intervention: No CMV infection
Number of subjects: 0
Study: 9113632

Group type: EXPERIMENTAL
Intervention: High-AA diet (1.7 g/d of arachidonic acid for 50 d)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-AA diet (210 mg/d of AA)
Number of subjects: 10
Study: 8403299

Group type: EXPERIMENTAL
Intervention: MK-383 (0.4 microgram.kg-1 x min-1)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: MK-383 (0.15 to 0.2 microgram.kg-1 x min-1)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 3100859

Group type: EXPERIMENTAL
Intervention: Topical acyclovir (ACV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trifluorothymidine (TFT)
Number of subjects: 0
Study: 30014968

Group type: EXPERIMENTAL
Intervention: Light load blood flow restriction resistance exercise (BFR‐RE) in ACLR patients (ACLR‐BFR)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Light load blood flow restriction resistance exercise (BFR‐RE) in non-injured individuals (NI‐BFR)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Heavy load resistance exercise (HL‐RE) in ACLR patients (ACLR‐HL)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Blood pressure measurement
Number of subjects: 3
Study: 28065190

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 1250μg (50 000 IU) weekly for 12 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Ergocalciferol 1250μg (50 000 IU) weekly for 12 weeks
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Cholecalciferol and Ergocalciferol
Number of subjects: 44
Study: 24410959

Group type: EXPERIMENTAL
Intervention: Spinal manipulation (0, 6, 12, or 18 sessions)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Light massage control
Number of subjects: 400
Study: 22317388

Group type: EXPERIMENTAL
Intervention: Improved weeding tools
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional tools
Number of subjects: 60
Study: 20799571

Group type: EXPERIMENTAL
Intervention: Subtotal abdominal hysterectomy (SAH)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Total abdominal hysterectomy (TAH)
Number of subjects: 150
Study: 18467303

Group type: EXPERIMENTAL
Intervention: Short-duration antimicrobial treatment (5 days)
Number of subjects: 3083
Study: 16874507

Group type: EXPERIMENTAL
Intervention: Elderly smokers
Number of subjects: 53

Group type: COMPARATOR
Intervention: Elderly smokers with 2 h abstinence
Number of subjects: 53

Group type: COMPARATOR
Intervention: Young non-smokers
Number of subjects: 53
Study: 12511761

Group type: EXPERIMENTAL
Intervention: Stroke Family Support Organiser (FSO) service
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 250
Study: 10728021

Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption (MAC)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Non-alcohol consuming patients (Control)
Number of subjects: 23
Study: 8649628

Group type: EXPERIMENTAL
Intervention: Microemulsion formulation of cyclosporin A
Number of subjects: 302
Study: 1308013

Group type: EXPERIMENTAL
Intervention: Air pollution exposure in Parel (SO2 levels up to 584 micrograms)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Air pollution exposure in Maravali
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Kerosene use
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Lung function tests (FVC, FEVI)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Air pollution exposure in Deonar
Number of subjects: 349
Study: 3912600

Group type: EXPERIMENTAL
Intervention: 0.5% levobunolol
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 1.0% levobunolol
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.5% timolol
Number of subjects: 50
Study: 31307055

Group type: EXPERIMENTAL
Intervention: CA+CSP
Number of subjects: 184

Group type: COMPARATOR
Intervention: HB+HSP
Number of subjects: 184
Study: 28700781

Group type: EXPERIMENTAL
Intervention: High-dose spironolactone (100 mg)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Usual care (placebo or 25 mg spironolactone)
Number of subjects: 360
Study: 27518920

Group type: EXPERIMENTAL
Intervention: Hippotherapy at walking pace
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hippotherapy at walk-trot pace
Number of subjects: 10

Group type: COMPARATOR
Intervention: Reference group (no treatment)
Number of subjects: 10
Study: 25163664

Group type: EXPERIMENTAL
Intervention: PRECIS and RE-AIM frameworks
Number of subjects: 0
Study: 22045829

Group type: EXPERIMENTAL
Intervention: tesaglitazar 2 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: pioglitazone 45 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: tesaglitazar 2 mg with ACE inhibitor
Number of subjects: 0
Study: 19707060

Group type: EXPERIMENTAL
Intervention: Personalized feedback
Number of subjects: 0
Study: 17290158

Group type: EXPERIMENTAL
Intervention: Isoflavone supplementation (70 mg/day) + exercise program (3 times per week)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Exercise program (3 times per week)
Number of subjects: 50
Study: 15625409

Group type: EXPERIMENTAL
Intervention: 200 mg cilostazol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 11717205

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 6

Group type: COMPARATOR
Intervention: Upright position
Number of subjects: 6
Study: 9602004

Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Number of subjects: 120

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 120
Study: 8150535

Group type: EXPERIMENTAL
Intervention: Radical cystectomy and pelvic-node dissection followed by adjuvant cisplatinum chemotherapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Radical cystectomy and pelvic-node dissection alone
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Concomitant carcinoma in situ
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Depth of invasion
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Morphological variables (deep invasion of the bladder wall and squamous differentiation)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Differentiation grade, pattern of growth, angioinvasive growth, glandular differentiation, concomitant prostate carcinoma (pT1)
Number of subjects: 70
Study: 2892392

Group type: EXPERIMENTAL
Intervention: Nizatidine 75 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cimetidine 300 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31039294

Group type: EXPERIMENTAL
Intervention: Burst spinal cord stimulation (SCS)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Tonic spinal cord stimulation (SCS)
Number of subjects: 7
Study: 30987919

Group type: EXPERIMENTAL
Intervention: Sugar-free fruit drinks
Number of subjects: 89

Group type: COMPARATOR
Intervention: Sugar-sweetened fruit drinks
Number of subjects: 89
Study: 28421316

Group type: EXPERIMENTAL
Intervention: Retroclavicular approach (group R)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Coracoid approach (group C)
Number of subjects: 100
Study: 25731690

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (200 mg daily) until 34 weeks and 6 days' gestation
Number of subjects: 390

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study: 24356937

Group type: EXPERIMENTAL
Intervention: Baseline heart rate >70 bpm
Number of subjects: 31531

Group type: EXPERIMENTAL
Intervention: Average heart rate in-trial
Number of subjects: 31531

Group type: EXPERIMENTAL
Intervention: For each 10 bpm increase in baseline and average heart rate
Number of subjects: 31531

Group type: EXPERIMENTAL
Intervention: Heart rate as a continuous variable
Number of subjects: 31531

Group type: EXPERIMENTAL
Intervention: Heart rate quintiles
Number of subjects: 31531

Group type: EXPERIMENTAL
Intervention: Heart rate
Number of subjects: 31531
Study: 21945107

Group type: EXPERIMENTAL
Intervention: Whole-pelvis concurrent chemoradiation (WP-CCRT)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Bladder-only concurrent chemoradiation (BO-CCRT)
Number of subjects: 230
Study: 19390070

Group type: EXPERIMENTAL
Intervention: Severe cerebral white matter hyperintensities (WMHs)
Number of subjects: 226

Group type: COMPARATOR
Intervention: No severe WMHs
Number of subjects: 226
Study: 17469099

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg/week, increased every 3 months if Disease Activity Score >2.4, tapered after 12 months
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 110
Study: 15262695

Group type: EXPERIMENTAL
Intervention: Thalidomide 100 mg/d
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Thalidomide 100 or 200 mg/d (after randomization)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Thalidomide treatment
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Neuropathy Impairment Score
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sural sensory nerve action potential amplitude
Number of subjects: 8
Study: 12225503

Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chloroquine (40 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfadoxine (500 mg) and Pyrimethamine (25 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quinine (30 mg/kg)
Number of subjects: 0
Study: 9522107

Group type: EXPERIMENTAL
Intervention: Ceftibuten 400 mg once daily
Number of subjects: 469

Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate 500 mg three times daily
Number of subjects: 469
Study: 9308538

Group type: EXPERIMENTAL
Intervention: fixed angle blade plate
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: compression hip screw
Number of subjects: 233

Group type: COMPARATOR
Intervention: implants not removed
Number of subjects: 233
Study: 2118025

Group type: EXPERIMENTAL
Intervention: Coronary Care Unit (CCU)
Number of subjects: 203

Group type: COMPARATOR
Intervention: General Wards (GW)
Number of subjects: 203
Study: 7213519

Group type: EXPERIMENTAL
Intervention: Spironolactone 25, 50, 100 and 200 mg daily
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 15
Study: 31883378

Group type: EXPERIMENTAL
Intervention: HbA1c > 8.0%
Number of subjects: 549

Group type: COMPARATOR
Intervention: HbA1c 6.1-7.0%
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: HbA1c ≤ 6.0%
Number of subjects: 549
Study: 30574780

Group type: EXPERIMENTAL
Intervention: High-catechin tea (HCT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control beverage
Number of subjects: 10
Study: 29063827

Group type: EXPERIMENTAL
Intervention: Adalimumab injections (80 mg and then 40 mg 2 weeks later) plus physiotherapy
Number of subjects: 332

Group type: COMPARATOR
Intervention: Saline injections plus physiotherapy
Number of subjects: 332
Study: 26407612

Group type: EXPERIMENTAL
Intervention: PVC conical-shaped tracheal tube
Number of subjects: 312

Group type: COMPARATOR
Intervention: PVC standard (barrel)-shaped tracheal tube
Number of subjects: 312
Study: 25524507

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 200/25 mcg
Number of subjects: 309

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 500 mcg
Number of subjects: 309
Study: 23751521

Group type: EXPERIMENTAL
Intervention: 5 mg/kg caffeine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 21975110

Group type: EXPERIMENTAL
Intervention: Prolonged-release melatonin (Circadin®) 2 mg daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 19594263

Group type: EXPERIMENTAL
Intervention: Food advertising during TV viewing (children)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Snack food advertising (adults)
Number of subjects: 2

Group type: COMPARATOR
Intervention: No food advertising (adults)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Food advertising promoting nutrition benefits (adults)
Number of subjects: 2
Study: 17033041

Group type: EXPERIMENTAL
Intervention: Awareness Through Movement (ATM)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control
Number of subjects: 33
Study: 15017504

Group type: EXPERIMENTAL
Intervention: Budesonide 6 mg/day
Number of subjects: 57

Group type: COMPARATOR
Intervention: Mesalamine 1 g 3 times/day
Number of subjects: 57
Study: 11156722

Group type: EXPERIMENTAL
Intervention: Tirofiban (0.1 microg/kg/min intravenously) + Enoxaparin (1 mg/kg sc q 12 hours)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Tirofiban (0.1 microg/kg/min intravenously) + Unfractionated heparin (intravenous, adjusted to activated partial thromboplastin time)
Number of subjects: 55
Study: 9660035

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily for 28 days prior to zolmitriptan administration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo daily for 28 days prior to zolmitriptan administration
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 10 mg oral dose
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Zolmitriptan alone or with fluoxetine
Number of subjects: 20
Study: 7972763

Group type: EXPERIMENTAL
Intervention: H‐1 MR spectroscopy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Myo‐inositol depletion
Number of subjects: 20
Study: 2521032

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's with 5% dextrose (LR5%D), 1 minute
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lactated Ringer's with 5% dextrose (LR5%D), 2 minutes
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lactated Ringer's (LR), 1 minute
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lactated Ringer's (LR), 2 minutes
Number of subjects: 80